Kyverna Therapeutics (KYTX) Balance Sheet: Assets & Liabilities

Kyverna Therapeutics (KYTX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Kyverna Therapeutics reported total assets of $293.83M and total liabilities of $61.55M. Shareholders' equity was $232.28M, down 12.9% from $266.59M a year earlier. Total debt stood at $28.71M against $279.25M in cash and short-term investments, a net cash position of $250.54M. That puts debt-to-equity at 0.12, compared with 0.03 a year earlier.

Kyverna Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Kyverna Therapeutics, Inc. (KYTX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Current Assets
Cash and Cash Equivalents	124.09	96.62	34.65	37.74	76.07
Short-Term Investments	155.16	189.36	22.90	13.59	0.00
Cash & Short-Term Investments	279.25	285.98	57.54	51.32	76.07
Accounts Receivable	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00
Other Current Assets	3.70	4.62	3.12	1.93	1.02
Total Current Assets	282.95	290.60	60.66	53.25	77.09
Non-Current Assets
Property, Plant & Equipment (Net)	5.42	10.66	10.61	12.44	7.81
Other Non-Current Assets	5.45	5.26	3.92	1.23	0.59
Total Non-Current Assets	10.87	15.92	14.53	13.67	8.40
Total Assets	293.83	304.65	75.20	66.92	85.49
Current Liabilities
Accounts Payable	5.31	4.62	4.36	1.45	0.77
Short-Term Debt	3.97	3.94	2.92	2.28	0.81
Accrued Liabilities	27.21	20.31	9.77	8.23	8.34
Deferred Revenue	0.00	0.00	0.00	0.00	6.00
Other Current Liabilities	27.21	25.19	12.58	0.57	8.34
Total Current Liabilities	36.49	33.76	19.86	11.95	15.93
Non-Current Liabilities
Long-Term Debt	24.74	4.30	6.16	8.29	4.74
Other Non-Current Liabilities	0.00	0.00	0.00	0.01	110.05
Total Non-Current Liabilities	25.06	4.30	6.16	8.29	115.81
Total Liabilities	61.55	38.06	26.02	20.25	131.74
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-424.83	-263.52	-136.04	-75.68	-46.78
Accumulated Other Comprehensive Income	0.10	0.11	0.00	-0.03	0.00
Additional Paid-in Capital	657.01	530.00	4.64	1.71	0.53
Shares Outstanding	60.39	43.21	43.12	40.82	40.82
Total Stockholders' Equity	232.28	266.59	49.18	46.68	-46.25
Total Liabilities & Equity	293.83	304.65	75.20	66.92	85.49

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kyverna Therapeutics Balance Sheet

How much debt does Kyverna Therapeutics have?

Kyverna Therapeutics had total debt of $28.71M as of Dec 31, 2025, against $279.25M in cash and short-term investments. Its debt-to-equity ratio was 0.12. Total debt was $8.24M a year earlier.

What are Kyverna Therapeutics's total assets?

Kyverna Therapeutics reported total assets of $293.83M as of Dec 31, 2025, down 3.6% from $304.64M a year earlier. Total liabilities were $61.55M.

What is Kyverna Therapeutics's shareholders' equity?

Kyverna Therapeutics's shareholders' equity was $232.28M as of Dec 31, 2025, or about $3.85 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition